Prot# IMCL CP13-0812: A Multicenter, Single-Arm, Phase 2 Study Evaluating IMC-A12 in Combination with Sorafenib as First-Line Systemic Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC)